SI
VIR icon

Sofinnova Investments’s Vir Biotechnology VIR Stock Holding History

Sofinnova Investments’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-300,000
Closed -$7.36M – 76
2023
Q2 		$7.36M Buy
+300,000
New +$7.53M 0.48% 35
2022
Q1 		– Sell
-200,000
Closed -$8.37M – 78
2021
Q4 		$8.37M Buy
+200,000
New +$7.84M 0.49% 47

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sofinnova Investments's VIR Position: Q2 2025 in Review

Sofinnova Investments sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 83,010 shares — an estimated $538K sold.

Sofinnova Investments first reported a position in VIR in Q1 2023 and held it in 6 quarters. The position peaked at $15.3M in Q1 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Sofinnova Investments reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Sofinnova Investments sold 83,010 Vir Biotechnology shares in Q2 2025, an estimated $538K.
  • Sofinnova Investments first reported a position in Vir Biotechnology in Q1 2023 and held it in 6 quarters.
  • Sofinnova Investments's Vir Biotechnology position peaked at $15.3M in Q1 2023.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.